Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Azenosertib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WEE1 known ✓ | P30291 | 20/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | PLK1 | P53350 | 1/20 | 1.00 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 1.00 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 1.00 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azenosertib SCHEMBL21333380 | 1.00 | WEE1 (1.00) | WEE1EGFRCYP3A4PLK1MAP3K19 | |
| Azenosertib SCHEMBL21350039 | 1.00 | WEE1 (1.00) | WEE1EGFRCYP3A4PLK1MAP3K19 | |
| Azenosertib SCHEMBL29482696 | 1.00 | WEE1 (1.00) | WEE1EGFRCYP3A4PLK1MAP3K19 | |
| Azenosertib SCHEMBL21333382 | 1.00 | WEE1 (1.00) | WEE1EGFRCYP3A4PLK1MAP3K19 | |
| Azenosertib SCHEMBL30712283 | 1.00 | WEE1 (1.00) | WEE1EGFRCYP3A4PLK1MAP3K19 | |
| SCHEMBL21332659 | 0.96 | WEE1 (1.00) | WEE1EGFRCYP3A4PLK1MAP3K19 | |
| SCHEMBL29482711 | 0.96 | WEE1 (1.00) | WEE1EGFRCYP3A4PLK1MAP3K19 | |
| SCHEMBL21332687 | 0.96 | WEE1 (1.00) | WEE1EGFRCYP3A4PLK1MAP3K19 | |
| SCHEMBL21350124 | 0.96 | WEE1 (1.00) | WEE1EGFRCYP3A4PLK1MAP3K19 | |
| SCHEMBL29986182 | 0.94 | WEE1 (0.89) | WEE1EGFRCYP3A4PLK1MAP3K19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260053799-A1 | COMPOUNDS FOR TREATING CANCER | EVEXTA BIO (FR) | 2026-02-26 | — | — | US | disclosed |
| EP-4568662-A1 | COMPOUNDS FOR TREATING CANCER | Evexta Bio (FR) | 2025-06-18 | — | — | EP | disclosed |
| CN-119997942-A | Compounds for the treatment of cancer | 埃维克斯塔生物公司 | 2025-05-13 | — | — | CN | disclosed |
| WO-2024033513-A1 | COMPOUNDS FOR TREATING CANCER | DIACCURATE (FR) | 2024-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260053799-A1 | COMPOUNDS FOR TREATING CANCER | NCOA1, AR, ESR2 | WEE1 1975/4885EGFR 53/4885CYP3A4 2215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.